NCT00517257

Atorvastatin for the Treatment of Retinal Vein Occlusion

Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO)

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: University of Toronto · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Accepted

Summary

The ATORVO study is designed to determine whether atorvastatin (Lipitor) can improve vision, when compared to placebo

Detailed description

Retinal vein occlusion (RVO), a common cause of visual loss in the Western world, is a disease whose etiology resembles that of classic atherosclerosis. A therapy that lowers the risk of arterial and venous thrombosis would seem to be a reasonable approach to managing this disease, for which there is currently no treatment. ATORVO is a randomized double-masked clinical trial comparing a daily dose of 80 mg of atorvastatin to matched placebo in persons recently diagnosed with RVO. At 24 weeks after randomization, we will evaluate each participant's visual acuity and the presence of secondary complications related to RVO.

Conditions

• Retinal Vein Occlusion
• Retinal Vein Thrombosis
• Central Retinal Vein Occlusion
• Branch Retinal Vein Occlusion
• Thrombosis

Interventions

Type	Name	Description
DRUG	Atorvastatin	80 mg orally once daily for 24 weeks
DRUG	Placebo	Placebo tablet orally once daily for 24 weeks

Timeline

• Start date: 2007-08-01
• Completion: 2009-09-01
• First posted: 2007-08-16
• Last updated: 2008-06-25

Locations

1 site across 1 country: Canada